ROIVANT SCIENCES LTD. Increase (Decrease) in Accrued Liabilities
ROIVANT SCIENCES LTD. (ROIV) reported Increase (Decrease) in Accrued Liabilities of -$13.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$13.91M.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $63.23M, a 569.98% increase year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $8.58M.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $12.52M, a 40.69% decline year-over-year.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for fiscal 2026 was $59.33M.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for fiscal 2025 was -$10.07M, a 125.08% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for fiscal 2024 was $40.15M, a 3.06% increase from fiscal 2023.
- ROIVANT SCIENCES LTD. increase (decrease) in accrued liabilities for fiscal 2023 was $38.96M, a 23.00% decline from fiscal 2022.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.91M 10-Q · filed 2026-08-06 | $49.31M derived: sum of 2 quarters · filed 2026-08-06 | $57.90M derived: sum of 3 quarters · filed 2026-08-06 | $70.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $63.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $71.81M derived: sum of 2 quarters · filed 2026-05-20 | $84.33M derived: sum of 3 quarters · filed 2026-05-20 | $59.33M 10-K · filed 2026-05-20 |
| 2025-12-31 | $8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $21.10M derived: sum of 2 quarters · filed 2026-02-06 | -$3.90M 10-Q · filed 2026-02-06 | $5.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $12.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$12.48M 10-Q · filed 2025-11-10 | -$3.04M derived: sum of 3 quarters · filed 2026-08-06 | -$6.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$25.00M 10-Q · filed 2026-08-06 | -$15.56M derived: sum of 2 quarters · filed 2026-08-06 | -$18.60M derived: sum of 3 quarters · filed 2026-08-06 | $2.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $6.40M derived: sum of 2 quarters · filed 2026-05-20 | $27.51M derived: sum of 3 quarters · filed 2026-05-20 | -$10.07M 10-K · filed 2026-05-20 |
| 2024-12-31 | -$3.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $18.08M derived: sum of 2 quarters · filed 2026-02-06 | -$19.51M 10-Q · filed 2026-02-06 | $36.43M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $21.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$16.47M 10-Q · filed 2025-11-10 | $39.46M derived: sum of 3 quarters · filed 2026-05-20 | $36.07M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$37.58M 10-Q · filed 2025-08-11 | $18.35M derived: sum of 2 quarters · filed 2026-05-20 | $14.96M derived: sum of 3 quarters · filed 2026-05-20 | $52.53M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $55.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $52.54M derived: sum of 2 quarters · filed 2026-05-20 | $90.11M derived: sum of 3 quarters · filed 2026-05-20 | $40.15M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $34.17M derived: sum of 2 quarters · filed 2025-02-10 | -$15.79M 10-Q · filed 2025-02-10 | $17.47M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $37.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$12.39M 10-Q · filed 2024-11-12 | $20.86M derived: sum of 3 quarters · filed 2025-05-29 | $25.12M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$49.96M 10-Q · filed 2024-08-09 | -$16.71M derived: sum of 2 quarters · filed 2025-05-29 | -$12.45M derived: sum of 3 quarters · filed 2025-05-29 | $7.17M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $33.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $37.51M derived: sum of 2 quarters · filed 2025-05-29 | $57.13M derived: sum of 3 quarters · filed 2025-05-29 | $38.96M 10-K · filed 2025-05-29 |
| 2022-12-31 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $23.88M derived: sum of 2 quarters · filed 2024-02-13 | $5.70M 10-Q · filed 2024-02-13 | $20.72M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $19.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $1.45M 10-Q · filed 2023-11-13 | $16.47M derived: sum of 3 quarters · filed 2023-11-13 | $33.47M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$18.18M 10-Q · filed 2023-08-14 | -$3.16M derived: sum of 2 quarters · filed 2023-08-14 | $13.85M derived: sum of 3 quarters · filed 2023-08-14 | $39.76M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $32.03M derived: sum of 2 quarters · filed 2023-06-28 | $57.94M derived: sum of 3 quarters · filed 2023-06-28 | $50.59M 10-K · filed 2023-06-28 |
| 2021-12-31 | $17.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $42.92M derived: sum of 2 quarters · filed 2023-02-13 | $35.58M 10-Q · filed 2023-02-13 | $45.80M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $25.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $18.57M 10-Q · filed 2022-11-14 | $28.80M derived: sum of 3 quarters · filed 2022-11-14 | $40.71M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$7.34M 10-Q · filed 2022-08-15 | $2.89M derived: sum of 2 quarters · filed 2022-08-15 | $14.80M derived: sum of 3 quarters · filed 2022-08-15 | $17.87M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $22.14M derived: sum of 2 quarters · filed 2022-06-28 | $25.21M derived: sum of 3 quarters · filed 2022-06-28 | $9.22M 10-K · filed 2022-06-28 |
| 2020-12-31 | $11.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | $14.98M derived: sum of 2 quarters · filed 2022-02-14 | -$1.00M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | -$12.91M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$15.98M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |